[CIS-PAGID] CVID + LIP

[Routes, John]

Elie
I think we need to get all interested parties together either in person or
by conference call to discuss. As we have had pretty good experience with
several patients using rituxin with imuran, it makes sense to have that as
one arm--plus If the patient does not tolerate imuran, we can substitute MMF
or another agreed upon drug-------the other arm is totally open and
personally would favor an arm without imuran----
Jack



John M. Routes, MD
Chief, Section of Allergy and Clinical Immunology
Professor of Pediatrics, Medicine, Microbiology and Molecular Genetics
Department of Pediatrics
Children's Hospital of Wisconsin
Medical College of Wisconsin
9000 W. Wisconsin Ave.
Milwaukee, WI  53226-4874
 
Phone: 414-456-4802; 414-266-6997
Fax: 414-456-6487 (Clinical)
Fax: 414-456-6323 (Laboratory)
Email: jroutes at mcw.edu
 




> From: Elie Haddad <elie.haddad at umontreal.ca>

> Reply-To: "pagid at list.clinimmsoc.org" <pagid at list.clinimmsoc.org>

> Date: Mon, 25 Jul 2011 09:56:30 -0500

> To: "pagid at list.clinimmsoc.org" <pagid at list.clinimmsoc.org>

> Subject: Re: [CIS-PAGID] CVID + LIP

> 

> Dear all,

> what do you think about comparing Rituximab to something else than Rituximab.

> Indeed, in the proposed protocol, Rituximab is in both arms meaning that we

> consider Rituximab as the gold standard therapy for this condition... I am a

> pro RTX in this condition but maybe there are other options, as outlined by

> Klaus.

> I would suggest to compare RTX to Steroids alone or also another possibility

> would be to compare RTX to Infliximab.

> Also, if finally we stay with the idea of RTX in both arms, what about MMF

> instead of Imuran ?

> Yours

> Elie

> 

> 

> 

> Elie Haddad, MD, PhD;

> Professor of Pediatrics, University of Montreal,

> Head, Pediatric Immunology and Rheumatology Division,

> CHU Sainte-Justine, 3175 Cote Sainte-Catherine

> Montreal, QC, H3T 1C5, Canada

> Ph: 1 514 345 4713

> fax: 1 514 345 4897

> e-mail: elie.haddad at umontreal.ca

> 

> 

> 

> 

> Le 2011-07-22 à 17:38, David Rawlings a écrit :

> 

>> As Jack and I have discussed previously, our group in Seattle would be keen

>> to participate in a trial- I suggest designing a 2 arm protocol eg Ritux

>> with or without Aza.

>> David

>> 

>> -----Original Message-----

>> From: pagid-bounces at list.clinimmsoc.org

>> [mailto:pagid-bounces at list.clinimmsoc.org] On Behalf Of Nelson, Robert P Jr

>> Sent: Friday, July 22, 2011 11:15 AM

>> To: pagid at list.clinimmsoc.org

>> Subject: Re: [CIS-PAGID] CVID + LIP

>> 

>> What about considering a mutlicenter clinical trial so we could contibute

>> our patients to an organized effort?  Bob

>> ________________________________________

>> From: pagid-bounces at list.clinimmsoc.org [pagid-bounces at list.clinimmsoc.org]

>> on behalf of Fleisher, Thomas (NIH/CC/DLM) [E] [TFleishe at cc.nih.gov]

>> Sent: Friday, July 22, 2011 10:32 AM

>> To: Routes, John; pagid at list.clinimmsoc.org

>> Subject: Re: [CIS-PAGID] CVID + LIP

>> 

>> Sorry for copying all on a simple question to Jack.

>> 

>> Thomas A. Fleisher, M.D.

>> Chief, Department of Laboratory Medicine

>> NIH Clinical Center

>> 301 496-5668 (T)

>> 301 402-1612 (F)

>> 

>> -----Original Message-----

>> From: Routes, John [mailto:jroutes at mcw.edu]

>> Sent: Friday, July 22, 2011 8:32 AM

>> To: pagid at list.clinimmsoc.org

>> Subject: Re: [CIS-PAGID] CVID + LIP

>> 

>> We have treated over ten patients with combination chemotherapy consisting

>> of rituxin and azathioprine with outstanding results no infections and in

>> many cased complete or near complete clearing.

>> 

>> Sent from my Verizon Wireless BlackBerry

>> 

>> ________________________________

>> From: Terri Tarrant <tarra002 at gmail.com>

>> Sender: "pagid-bounces at list.clinimmsoc.org"

>> <pagid-bounces at list.clinimmsoc.org>

>> Date: Fri, 22 Jul 2011 06:16:47 -0500

>> To: pagid at list.clinimmsoc.org<pagid at list.clinimmsoc.org>

>> ReplyTo: "pagid at list.clinimmsoc.org" <pagid at list.clinimmsoc.org>

>> Subject: Re: [CIS-PAGID] CVID + LIP

>> 

>> Yes, we have 3 cases that responded well (2 with CVID and 1 idiopathic LIP).

>> We used the Eisenberg protocol of 1 g IV day 0 and day 14 with 100 mg IV

>> solumedrol pre-med.  We did not use in combination with other drugs.  We did

>> not see an increase in infections.  All patients needed redosing at 9-12

>> month intervals.

>> 

>> Terri Tarrant

>> 

>> On Thu, Jul 21, 2011 at 10:07 PM, Church, Joseph

>> <JChurch at chla.usc.edu<mailto:JChurch at chla.usc.edu>> wrote:

>> Colleagues:

>> 

>> A 60yo female with long term CVID has had lymphoid interstitial pneumonitis

>> that was biopsy documented in 2005.

>> 

>> She had developed worsening of symptoms over the past 6 months.

>> 

>> She is trying to avoid increasing her prednisone, currently at 10mg/d,

>> because of coronary artery disease and hypertension; she could not tolerate

>> CellCept.

>> 

>> Has anyone tried Rituximab in this setting?

>> 

>> Joe Church, MD

>> Children's Hospital Los Angeles

>> 

>> 

>> 

>> ---------------------------------------------------------------------

>> CONFIDENTIALITY NOTICE: This e-mail message, including any attachments,

>> is for the sole use of the intended recipient(s) and may contain

>> confidential

>> or legally privileged information. Any unauthorized review, use, disclosure

>> or distribution is prohibited. If you are not the intended recipient, please

>> contact the sender by reply e-mail and destroy all copies of this original

>> message.

>> ---------------------------------------------------------------------

>> 

>> 

>> 

>> --

>> Terri Tarrant, MD

>> Assistant Professor of Medicine

>> Thurston Arthritis Research Center

>> Lineberger Cancer Center Member

>> CB # 7280, 3300 Manning Dr.

>> Chapel Hill, NC 27599

>> (919) 843-4727

>> http://tarc.med.unc.edu/tarrant_welcome.php

>> 

>> 

>> 

>> 

>